CNS/Neurology Market Research Reports & Industry Analysis
A neurologist is a medical doctor that specializes in the diagnosis, treatment and management of illnesses affecting the brain, spinal cord, and nervous system. Neurologists must complete at least three years of specialized training in neurology, after completing medical school. A neurosurgeon must go through much more extensive and rigorous schooling and training. On top of diagnosing and treating neurological disorders, neurosurgeons can also perform surgery on the brain, spinal cord, and nerves.
Pharmaceuticals in CNS/Neurology are one of leading fields in medicine in terms of funding and research. On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology. Many of the therapeutic drugs used to treat CNS/Neurological disorders have lost their patent protection or market exclusivity, leading to greater research and market opportunities for competing pharmaceutical and medical device companies. Despite the widespread use of CNS drugs, knowledge of these agents is limited due to the anatomic and neurochemical complexity of the brain and spinal cord.
CNS/Neurology Industry Research & Market Reports
-
Hydrocephalus Shunt Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2035
... by the rising prevalence of hydrocephalus, growing geriatric and pediatric populations, and increasing adoption of advanced shunt technologies. Hydrocephalus, a neurological disorder characterized by excess cerebrospinal fluid accumulation in the brain, is being increasingly treated ... Read More
-
Behavioral Mental Health Care Software Market Report by Solution (Software, Services), Function (Clinical Functionality, Administrative Functionality, Financial Functionality), Disorder Type (Anxiety, Post-Traumatic Stress Disorder (PSTD), Substance Abuse, Schizophrenia, Bipolar Disorders, and Others), Delivery Model (Subscription Model, Ownership Model), End Use (Providers, Payers, Patients), and Region 2025-2033
... 10.11% during 2025-2033. The growth of the market is driven by the increasing advent of technologies in the healthcare sector, surging prevalence of mental health disorders, and the rising awareness regarding the mental illness. Global ... Read More
-
Cranial Fixation and Stabilization Systems
... Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Cranial Stabilization Systems, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$987.5 ... Read More
-
Amyotrophic Lateral Sclerosis
... at a CAGR of 19.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR The Amyotrophic Lateral Sclerosis market in the U.S. ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Intracranial Pressure (ICP) Monitoring Devices
... Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Invasive, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$2.4 Billion by ... Read More
-
EEG, EMG and Evoked Potential Devices
... reach US$1.7 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Electroencephalograph Equipment, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach ... Read More
-
Neurology Devices
... CAGR of 5.9% over the analysis period 2024-2030. Cerebrospinal Fluid Management, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$7.1 Billion by the end of the ... Read More
-
Autism Spectrum Disorder Treatment
... 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Stimulants, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$1.4 Billion by the end ... Read More
-
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
... reach US$57.7 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Stimulant, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$47.7 ... Read More
-
Opioids
... 2.3% over the analysis period 2024-2030. Extended-Release / Long-Acting, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$18.7 Billion by the end of the analysis period. ... Read More
-
Neurovascular Devices / Interventional Neurology
... Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Aneurysm Coiling & Embolization Devices, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and ... Read More
-
Neuroscience
... 3.9% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$29.9 Billion by the end of the analysis period. Growth in ... Read More
-
Brain Health Supplements
... at a CAGR of 5.4% over the analysis period 2024-2030. Natural Molecules, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$6.8 Billion by the end of ... Read More
-
Antipsychotic Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Schizophrenia, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$13.6 Billion by the end of the analysis period. ... Read More
-
Intracranial Aneurysm
... CAGR of 8.7% over the analysis period 2024-2030. Endovascular Coiling, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Acute Repetitive Seizures
... at a CAGR of 45.4% over the analysis period 2024-2030. Diastat Rectal Gel, one of the segments analyzed in the report, is expected to record a 46.9% CAGR and reach US$8.4 Billion by the end ... Read More
-
Anxiolytics
... 4.6% over the analysis period 2024-2030. The U.S. Market is Estimated at US$259.8 Million While China is Forecast to Grow at 7.1% CAGR The Anxiolytics market in the U.S. is estimated at US$259.8 Million in ... Read More
-
Neuroprotection Therapeutics
... CAGR of 6.9% over the analysis period 2024-2030. Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$45.7 Billion by the end ... Read More
-
Brain Computer Interface
... at a CAGR of 10.3% over the analysis period 2024-2030. Invasive BCI, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$1.5 Billion by the end of ... Read More
-
Spinal Muscular Atrophy
... at a CAGR of 12.3% over the analysis period 2024-2030. Type 1, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$2.4 Billion by the end of ... Read More
-
Anxiety Disorder Treatment
... at a CAGR of 2.4% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$4.9 Billion by the end of the ... Read More
-
Neurodegenerative Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Dopamine Agonist, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.7 Billion by the end of the analysis ... Read More
-
Contract Research Organization Services (CROs)
... Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Clinical Research, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$76.7 Billion ... Read More
-
CNS Therapeutics
... CAGR of 7.3% over the analysis period 2024-2030. Neurodegenerative Diseases, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$75.9 Billion by the end of the analysis ... Read More
Research Assistance
